Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, Coelho H, Fossard G, Barraco F, Galicier L, Bienvenu B, Hirsch P, Vial G, Boutin AB, Galland J, Le Guenno G, Bigot A, Warrington KJ, Kermani TA, Grayson PC, Patel BA, Beck DB, Jamilloux Y, Fenaux P, Sujobert P.
Heiblig M, et al. Among authors: fossard g.
Blood. 2022 Aug 25;140(8):927-931. doi: 10.1182/blood.2022016642.
Blood. 2022.
PMID: 35609174
Free PMC article.